EVNIN LUKE 4

4 · Werewolf Therapeutics, Inc. · Filed Jun 10, 2026

AI-generated summary of this filing

Updated Jun 10, 2026

Werewolf Therapeutics (HOWL) Director Luke Evnin Sells 76,928 Shares

What Happened

Luke Evnin, a director of Werewolf Therapeutics, sold 76,928 shares (reported as a sale) on June 9, 2026. The weighted-average price was $0.37 per share for total proceeds of $28,463. The sales were executed in multiple transactions at prices ranging from $0.3553 to $0.3851.

Key Details

Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely).
Transaction type: Sale (Code S), effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026 (F1).
Price: Weighted average $0.37; individual trades ranged $0.3553–$0.3851 (F3). Reporting person can provide per-trade prices on request.
Breakdown of shares sold by related entities: 8,242 by MPM Asset Management LLC, 52,039 by MPM BioVentures 2014, L.P., 3,471 by MPM BioVentures 2014(B), L.P., 1,791 by MPM Asset Management Investors BV2014 LLC, and 11,385 by MPM Oncology Innovations Fund, L.P. (F2).
Shares held after the transaction (across listed entities): 32,171 (AM LLC), 203,135 (BV 2014), 13,546 (BV 2014(B)), 6,989 (AM BV2014), and 44,442 (MPM OIF) — total 300,283 shares held across those entities (F5).
Relationship/beneficial ownership note: Evnin is a member/manager/director of the listed investment entities and disclaims direct beneficial ownership except to the extent of his pecuniary interest (F4).

Context

This was a sale under a pre-established 10b5-1 plan, which is a routine way insiders automate trades and does not, by itself, indicate the insider’s view on the company. The sale was executed by affiliated investment entities rather than as a personal open-market block by Evnin.

Form 4

Period: 2026-06-09

Director

Transactions

Sale
Common Stock
[F1][F2][F3][F4][F5]
2026-06-09$0.37/sh−76,928$28,463→ 300,283 total(indirect: See Footnotes)

Footnotes (5)

[F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
[F2]The shares were sold as follows: 8,242 by MPM Asset Management LLC ("AM LLC"), 52,039 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,471 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,791 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,385 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3553 to $0.3851 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
[F5]The shares are held as follows: 32,171 by AM LLC, 203,135 by BV 2014, 13,546 by BV 2014(B), 6,989 by AM BV2014 and 44,442 by MPM OIF.

Signature

/s/ Luke Evnin|2026-06-10

1 file